Reported about 2 months ago
Viking Therapeutics (VKTX) has gained significant attention in the biotech sector this year, with its stock surging nearly 250%. The company is developing innovative treatments for obesity, including a monthly injection and an oral pill, targeting the lucrative $150 billion market. Expert Matt Higgins suggests that Viking's potential acquisition value could reach $15 billion, highlighting its promising research and upcoming conference where new findings may be announced.
Source: YAHOO